Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4589 On Other Exchanges
Symbol
Exchange
4589 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

acucela inc (4589) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACUCELA INC (4589)

Related News

No related news articles were found.

acucela inc (4589) Related Businessweek News

No Related Businessweek News Found

acucela inc (4589) Details

Acucela Inc. discovers and develops therapeutic products to treat and slow the progression of sight-threatening ophthalmic diseases worldwide. It focuses on developing oral products based on its proprietary visual cycle modulation (VCM) compounds to address various retinal diseases, primarily age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, as well as potentially Stargardt disease, retinitis pigmentosa, and retinopathy of prematurity. The company’s product candidates include Emixustat hydrochloride, which is in Phase IIb/III clinical trial for the treatment of age-related macular degeneration; and OPA-6566, an adenosine A2a receptor agonist that is in Phase I/II clinical trial to treat ocular hypertension and open-angle glaucoma as a topical ophthalmic solution. It has a co-development and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. for Emixustat and OPA-6566. Acucela Inc. was founded in 2002 and is based in Seattle, Washington.

Founded in 2002

acucela inc (4589) Top Compensated Officers

Founder and Chairman
Total Annual Compensation: $521.9K
Vice President of Human Resources
Total Annual Compensation: $259.5K
Compensation as of Fiscal Year 2013.

acucela inc (4589) Key Developments

Acucela Inc. Announces Management Changes; Announces Non-Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year Ending December 31, 2015

Acucela Inc. announced that on March 24, 2015, Dewey h. Blocker, Jr. was appointed as the company’s vice president of finance, secretary and treasurer and will serve as interim principal accounting officer and interim principal financial officer, effective march 24, 2015, under the terms of a letter agreement. Mr. blocker will oversee all finance operations until a new chief financial officer is appointed. Brian O'Callaghan will no longer serve as interim chief financial officer, secretary, and treasurer of the company effective march 24, 2015. Mr. O'Callaghan will continue to serve as the company’s chief executive officer and president. Mr. Blocker joined the company in 2008 as Director of Finance and in 2010 was promoted to Senior Director of Finance. The company announced non-consolidated earnings results for the year ended December 31, 2014. For the year, the company reported revenues from collaborations of USD 35,396,000 compared to USD 52,947,000 a year ago. Loss from operations was USD 188,000 compared to income from operations of USD 6,994,000 a year ago. Income before income tax was USD 353,000 compared to USD 7,182,000 a year ago. Net loss attributable to common shareholders was USD 2,006,000 or USD 0.06 per basic and diluted share compared to net income attributable to common shareholders of USD 1,161,000 or USD 0.09 per diluted share a year ago. Net cash provided by operating activities was USD 8,844,000 compared to USD 7,246,000 a year ago. Additions to property and equipment were USD 131,000 compared to USD 500,000 a year ago. For the full year ending December 31, 2015, the company expects revenues from collaborations in the range of USD 33,200,000 to USD 35,700,000, loss from operations in the range of USD 9,575,000 to USD 12,000,000, loss before income tax in the range of USD 9,225,000 to USD 11,575,000 and net loss in the range of USD 9,350,000 to USD 11,650,000 or net loss per share in the range of USD 0.26 to USD 0.33.

Acucela Inc. Announces Board Appointments

Acucela Inc. announced that Brian O’Callaghan, the company’s President and Chief Operating Officer, will assume the role of Chief Executive Officer, along with continuing to serve as Interim Chief Financial Officer. Ryo Kubota, M.D., Ph.D., the company’s Founder, will retain his position as Chairman of the company’s Board of Directors. Mr. O’Callaghan will assume the role of CEO effective January 1, 2015.

Acucela Inc. Revises Earnings Guidance for the Year Ending December 31, 2014

Acucela Inc. revised earnings guidance for the year ending December 31, 2014. For the year, the company now expects revenue from collaborations to be $34,739,000 against previously expected of $61,840,000. Operating income to be $693,000 against previously expected of $836,000. Income before income tax to be $250,000 against previously expected of $433,000. Net loss to be $1,997,000 or $0.06 per share against previously expected net income of $264,000 or $0.02 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4589:JP ¥667.00 JPY -3.00

4589 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4589.
View Industry Companies
 

Industry Analysis

4589

Industry Average

Valuation 4589 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.6x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACUCELA INC, please visit www.acucela.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.